Abstract

NANOTECHNOLOGY-MEDIATED NOSE TO BRAIN DRUG DELIVERY FOR PARKINSON’S DISEASE: A MINI REVIEW

Prathibha Pavuluri*, Mounica Velmula and Uma Maheswara Rao

ABSTRACT

The blood brain barrier (BBB) represents a stringent barrier for delivery of neurotherapeutics in-vivo. An attempt to overcome this barrier is represented by the direct transport of drugs from the nose to the brain along the olfactory and trigeminal nerve pathways. These nerve pathways initiate in the nasal cavity at olfactory neuroepithelium and terminate in the brain. An enormous range of neurotherapeutics, both macromolecules and low molecular weight drugs, can be delivered to the central nervous system (CNS) via this route. Nanoparticle (NP) therapeutics is an emerging modality for the treatment of Parkinson‟s disease (PD) as it offers targeted delivery and enhances the therapeutic efficacy and/or bioavailability of neurotherapeutics. This is relevant in the field of drug delivery as well as for new developments in nanotechnology.

Keywords: Blood–brain barrier, brain–blood ratio, nanotechnology, nasal drug delivery, neurodegenerative disorders, nose to brain, Parkinson?s disease.